Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 134685, 13 pages
http://dx.doi.org/10.1155/2015/134685
Research Article

Neuroprotective Effect of Xueshuantong for Injection (Lyophilized) in Transient and Permanent Rat Cerebral Ischemia Model

1Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
2Tianjin Key Laboratory of Chinese Medicine Pharmacology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
3Zhongnuo R&D Department, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Hebei 050051, China

Received 30 July 2015; Revised 2 November 2015; Accepted 8 November 2015

Academic Editor: Chang-Gue Son

Copyright © 2015 Xumei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Matsuo, M. Kamouchi, T. Ago et al., “Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry,” Geriatrics & Gerontology International, vol. 14, no. 4, pp. 954–959, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Grotta, W. S. Burgin, A. El-Mitwalli et al., “Intravenous tissue-type plasminogen activator therapy for ischemic stroke, Houston experience 1996 to 2000,” Archives of Neurology, vol. 58, no. 12, pp. 2009–2013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. J. De Keyser, M. Uyttenboogaart, M. W. Koch et al., “Neuroprotection in acute ischemic stroke,” Acta Neurologica Belgica, vol. 105, no. 3, pp. 144–148, 2005. View at Google Scholar · View at Scopus
  4. D. Brea, M. Blanco, P. Ramos-Cabrer et al., “Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values,” Journal of Cerebral Blood Flow & Metabolism, vol. 31, no. 6, pp. 1424–1431, 2011. View at Publisher · View at Google Scholar
  5. C. Zuany-Amorim, J. Hastewell, and C. Walker, “Toll-like receptors as potential therapeutic targets for multiple diseases,” Nature Reviews Drug Discovery, vol. 1, no. 10, pp. 797–807, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Qiu, M. Nishimura, Y. Wang et al., “Early release of HMGB-1 from neurons after the onset of brain ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 5, pp. 927–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Shichita, E. Hasegawa, A. Kimura et al., “Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain,” Nature Medicine, vol. 18, no. 6, pp. 911–917, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. X. M. Wang, S. X. Wang, and L. M. Hu, “Neuroprotective effect of panax notoginseng saponins and its main components,” World Journal of Neuroscience, vol. 4, no. 1, pp. 12–17, 2014. View at Publisher · View at Google Scholar
  9. C. Iadecola and J. Anrather, “The immunology of stroke: from mechanisms to translation,” Nature Medicine, vol. 17, no. 7, pp. 796–808, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. Shang, H. Xu, Z. Liu, K. Chen, and J. Liu, “Oral Panax notoginseng preparation for coronary heart disease: a systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 940125, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Vongsangnak, J. Gua, S. Chauvatcharin, and J.-J. Zhong, “Towards efficient extraction of notoginseng saponins from cultured cells of Panax notoginseng,” Biochemical Engineering Journal, vol. 18, no. 2, pp. 115–120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Xu, P. Huang, Z. Yu et al., “Efficacy and safety of Panax notoginseng saponin therapy for acute intracerebral hemorrhage, meta-analysis, and mini review of potential mechanisms of action,” Frontiers in Neuroscience, vol. 7, pp. 274–293, 2015. View at Google Scholar
  13. K.-T. Choi, “Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer,” Acta Pharmacologica Sinica, vol. 29, no. 9, pp. 1109–1118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L.-Q. Jin and L. Shi, “Effects of saponins of Panax notoginseng on sodium-potassium-adenosine triphosphatase and calcium-magnesium-adenosine triphosphatase,” Zhongguo Yao Li Xue Bao, vol. 12, no. 6, pp. 504–506, 1991. View at Google Scholar · View at Scopus
  15. J. Zhu, X. Fan, Y. Cheng et al., “Chemometric analysis for identification of botanical raw materials for pharmaceutical use: a case study using Panax notoginseng,” PLoS ONE, vol. 9, no. 1, Article ID e87462, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. Southern Medicine Economic Research Institute, “The 2014 blue book of the development of Chinese pharmaceutical market,” Progress in Pharmaceutical Sciences, vol. 38, no. 7, pp. 481–496, 2014. View at Google Scholar
  17. D. J. Lin, “HPLC fingerprints of freeze-dried xueshuantong for injection,” China Pharmacy, vol. 20, no. 33, pp. 2606–2608, 2009. View at Google Scholar
  18. P. Fu and Z. Y. Liu, “Determination of the effecient elements of Xuesaitong for injection, Xueshuantong injection and Xuemaitong for injection by fingerprint,” West China Journal of Pharmaceutical Sciences, vol. 22, no. 1, pp. 76–78, 2007. View at Google Scholar
  19. M. Sawada, N. J. Alkayed, S. Goto et al., “Estrogen receptor antagonist ICI182,780 exacerbates ischemic injury in female mouse,” Journal of Cerebral Blood Flow and Metabolism, vol. 20, no. 1, pp. 112–118, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Fisher, G. Feuerstein, D. W. Howells et al., “Update of the stroke therapy academic industry roundtable preclinical recommendations,” Stroke, vol. 40, no. 6, pp. 2244–2250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. B. Bederson, L. H. Pitts, M. Tsuji, M. C. Nishimura, R. L. Davis, and H. Bartkowski, “Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination,” Stroke, vol. 17, no. 3, pp. 472–476, 1986. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Kuang, Y.-S. Chen, L.-F. Wang et al., “Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer's disease mouse model,” Neurobiology of Aging, vol. 35, no. 1, pp. 169–178, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. C. V. Borlongan and P. R. Sanberg, “Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism,” The Journal of Neuroscience, vol. 15, no. 7, pp. 5372–5378, 1995. View at Google Scholar · View at Scopus
  24. M. De Ryck, J. Van Reempts, M. Borgers, A. Wauquier, and P. A. J. Janssen, “Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats,” Stroke, vol. 20, no. 10, pp. 1383–1390, 1989. View at Publisher · View at Google Scholar · View at Scopus
  25. K. L. Schaar, M. M. Brenneman, and S. I. Savitz, “Functional assessments in the rodent stroke model,” Experimental and Translational Stroke Medicine, vol. 2, article 13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Sugiura, K. Kitagawa, S. Tanaka et al., “Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats,” Stroke, vol. 36, no. 4, pp. 859–864, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. I. B. Nieradko and A. Borzêcki, “Effect of cypermethrin on memory, movement activity and coordination in mice after transient incomplete cerebral ischemia,” Pharmacological Reports, vol. 60, no. 5, pp. 699–705, 2008. View at Google Scholar
  28. P. Zhang, W. Li, L. Li et al., “Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury,” Neuroscience, vol. 201, pp. 297–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Carrithers, S. Tandon, S. Canosa, M. Michaud, D. Graesser, and J. A. Madri, “Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice,” The American Journal of Pathology, vol. 166, no. 1, pp. 185–196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. C. Chen, J. S. Wu, S. T. Yang et al., “Stroke, angiogenesis and phytochemicals,” Frontiers in Bioscience, vol. 4, pp. 599–610, 2012. View at Google Scholar
  31. G. J. Del Zoppo, “Inflammation and the neurovascular unit in the setting of focal cerebral ischemia,” Neuroscience, vol. 158, no. 3, pp. 972–982, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. C. Cramer, “Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery,” Annals of Neurology, vol. 63, no. 3, pp. 272–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-S. Lee, J.-H. Song, N.-W. Sohn, and J.-W. Shin, “Inhibitory effects of ginsenoside Rb1 on neuroinflammation following systemic lipopolysaccharide treatment in mice,” Phytotherapy Research, vol. 27, no. 9, pp. 1270–1276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Liu and J.-T. Zhang, “Effects of ginsenoside Rg1 on c-fos gene expression and cAMP levels in rat hippocampus,” Zhongguo Yao Li Xue Bao, vol. 17, no. 2, pp. 171–174, 1996. View at Google Scholar · View at Scopus
  35. Z.-Y. Chen, T.-M. Du, and S.-C. Chen, “Effects of ginsenoside Rg1 on learning and memory function and morphology of hippocampal neurons of rats with electrical hippocampal injuries,” Journal of Southern Medical University, vol. 31, no. 6, pp. 1039–1042, 2011. View at Google Scholar · View at Scopus
  36. R. Ye, X. Kong, Q. Yang, Y. Zhang, J. Han, and G. Zhao, “Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice,” Neuropharmacology, vol. 61, no. 4, pp. 815–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Ye, X. Zhang, X. Kong et al., “Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia,” Neuroscience, vol. 178, pp. 169–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. L.-M. Chen, X.-M. Zhou, Y.-L. Cao, and W.-X. Hu, “Neuroprotection of ginsenoside Re in cerebral ischemia-reperfusion injury in rats,” Journal of Asian Natural Products Research, vol. 10, no. 5, pp. 439–445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Gu, N. Nakamichi, W.-S. Zhang et al., “Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly,” Journal of Neuroscience Research, vol. 87, no. 9, pp. 2145–2156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Kikuchi, K.-I. Kawahara, S. Tancharoen et al., “The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 3, pp. 865–874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Okamura, T. Tsubokawa, H. Johshita, H. Miyazaki, and Y. Shiokawa, “Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia,” Neurological Research, vol. 36, no. 1, pp. 65–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. C. L. Willis, “Glia-induced reversible disruption of blood-brain barrier integrity and neuropathological response of the neurovascular unit,” Toxicologic Pathology, vol. 39, no. 1, pp. 172–185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Lv, Y. Liu, J. Zhang et al., “Roles of inflammation response in microglia cell through Toll-like receptors 2/interleukin-23/interleukin-17 pathway in cerebral ischemia/reperfusion injury,” Neuroscience, vol. 176, pp. 162–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-H. Yi, S.-W. Park, R. Kapadia, and R. Vemuganti, “Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage,” Neurochemistry International, vol. 50, no. 7-8, pp. 1014–1027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Rashidian, M. W. Rousseaux, K. Venderova et al., “Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo,” The Journal of Neuroscience, vol. 29, no. 40, pp. 12497–12505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. K.-S. Yang, S. W. Kang, H. A. Woo et al., “Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid,” The Journal of Biological Chemistry, vol. 277, no. 41, pp. 38029–38036, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. L. T. Kong, Pharmacokinetic Study of Ginseng Saponins, Peking Union Medical College, 2013.